Boldine-Derived Alkaloids Inhibit the Activity of DNA Topoisomerase I and Growth of Mycobacterium tuberculosis

The spread of multidrug-resistant isolates of Mycobacterium tuberculosis requires the discovery of new drugs directed to new targets. In this study, we investigated the activity of two boldine-derived alkaloids, seconeolitsine (SCN) and N-methyl-seconeolitsine (N-SCN), against M. tuberculosis. These...

ver descrição completa

Detalhes bibliográficos
Autores: García Esteban, María Teresa, Carreño, David, Tirado Vélez, José Manuel, Ferrándiz, María José, Rodrigues, Liliana, Gracia, Begoña, Amblar, Mónica, Ainsa, José A., Gonzalez de la Campa, Adela
Formato: artículo
Fecha de publicación:2018
País:España
Recursos:Universidad Complutense de Madrid (UCM)
Repositorio:Docta Complutense
Idioma:inglés
OAI Identifier:oai:docta.ucm.es:20.500.14352/112403
Acesso em linha:https://hdl.handle.net/20.500.14352/112403
Access Level:acceso abierto
Palavra-chave:579.61
616.24-002.5
616.9
577.1
577.2
615.012
Mycobacterium tuberculosis
DNA topoisomerase I inhibitor
DNA supercoiling
N-methylseconeolitsine
Seconeolitsine
Antituberculosis activity
Drug discovery
Microbiología (Biología)
Biología molecular (Biología)
Enfermedades infecciosas
Medicamentos
2414 Microbiología
2403 Bioquímica
2415 Biología Molecular
3201.03 Microbiología Clínica
3205.05 Enfermedades Infecciosas
3209.08 Preparación de Medicamentos
Descrição
Resumo:The spread of multidrug-resistant isolates of Mycobacterium tuberculosis requires the discovery of new drugs directed to new targets. In this study, we investigated the activity of two boldine-derived alkaloids, seconeolitsine (SCN) and N-methyl-seconeolitsine (N-SCN), against M. tuberculosis. These compounds have been shown to target DNA topoisomerase I enzyme and inhibit growth of Streptococcus pneumoniae. Both SCN and N-SCN inhibited M. tuberculosis growth at 1.95–15.6 μM, depending on the strain. In M. smegmatis this inhibitory effect correlated with the amount of topoisomerase I in the cell, hence demonstrating that this enzyme is the target for these alkaloids in mycobacteria. The gene coding for topoisomerase I of strain H37Rv (MtbTopoI) was cloned into pQE1 plasmid of Escherichia coli. MtbTopoI was overexpressed with an N-terminal 6-His-tag and purified by affinity chromatography. In vitro inhibition of MtbTopoI activity by SCN and N-SCN was tested using a plasmid relaxation assay. Both SCN and N-SCN inhibited 50% of the enzymatic activity at 5.6 and 8.4 μM, respectively. Cleavage of single-stranded DNA was also inhibited with SCN. The effects on DNA supercoiling were also evaluated in vivo in plasmid-containing cultures of M. tuberculosis. Plasmid supercoiling densities were −0.060 in cells untreated or treated with boldine, and −0.072 in 1 × MIC N-SCN treated cells, respectively, indicating that the plasmid became hypernegatively supercoiled in the presence of N-SCN. Altogether, these results demonstrate that the M. tuberculosis topoisomerase I enzyme is an attractive drug target, and that SCN and N-SCN are promising lead compounds for drug development.